<DOC>
	<DOC>NCT02481518</DOC>
	<brief_summary>The purpose of this study is to determine whether magnesium preloading reduce incident of cisplatin induced acute kidney injury in head and neck cancer who receiving low dose cisplatin (40 mg/m2 weekly for 7 weeks).</brief_summary>
	<brief_title>Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity</brief_title>
	<detailed_description>Randomized controlled trial comparing efficacy of magnesium preloading versus normal saline for prevention of acute and chronic nephrotoxicity of cisplatin.</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age &gt; 18 years Eastern Cooperative Oncology Group score 02 First Diagnosed Head and neck cancer and plan for treatment with cisplatin Serum creatinine ≤1.5 mg/dl or eGFR≥60(ml/min/1.73 m2) Prior treatment with cisplatin before randomization Uncontrolled concurrent disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cisplatin nephrotoxicity</keyword>
	<keyword>Acute kidney injury</keyword>
</DOC>